Kiniksa Pharmaceuticals International

KNSA | NASDAQ

$78.51

+$0.38 (+0.49%)

Sep 22, 2026, 12:07 PM ET · Market open

Fiscal Year Period Ending	FY 2025 Dec 30, 2025	FY 2024 Dec 30, 2024	FY 2023 Dec 30, 2023	FY 2022 Dec 30, 2022	FY 2021 Dec 30, 2021	FY 2020 Dec 30, 2020
Net Income	-43.19M	-43.19M	14.08M	183.36M	-157.92M	-161.38M
Depreciation & Amortization	1.7M	1.7M	2.34M	2.4M	2.36M	2.41M
Stock-Based Compensation	30.69M	30.69M	27.15M	25.12M	25.17M	20.88M
Other Working Capital	27.05M	46.82M	11.48M	5.65M	6.91M	654K
Other Non-Cash Items	-23.27M	3.55M	2.17M	2.99M	3.4M	1.52M
Deferred Income Tax	8.13M	8.13M	-33.79M	-185.5M	11K	4.36M
Change in Working Capital	51.63M	24.81M	1.35M	-22.58M	689K	-4.32M
Operating Cash Flow	25.69M	25.69M	13.3M	5.81M	-126.3M	-136.53M
Capital Expenditures	-277K	-277K	-130K	-105K	-20.42M	-283K
Cash Acquisitions	n/a	25K	n/a	n/a	n/a	23.16M
Purchase of Investments	-202.01M	-202.01M	-204.93M	-135.86M	-157.25M	-430.21M
Sales Maturities Of Investments	239.94M	239.94M	175.51M	127.8M	306.3M	407.05M
Other Investing Acitivies	25K	n/a	n/a	91K	-20M	-23.16M
Investing Cash Flow	37.67M	37.67M	-29.56M	-8.08M	128.64M	-23.44M
Debt Repayment	n/a	n/a	n/a	n/a	n/a	n/a
Common Stock Repurchased	-7.73M	-4.98M	-2.21M	n/a	n/a	n/a
Dividend Paid	n/a	n/a	n/a	n/a	n/a	n/a
Other Financial Acitivies	20M	17.25M	3.7M	-901K	n/a	-1.14M
Financial Cash Flow	12.27M	12.27M	1.5M	2.52M	5.89M	227.09M
Net Cash Flow	75.63M	75.63M	-14.76M	245K	8.22M	67.11M
Free Cash Flow	25.41M	25.41M	13.17M	5.7M	-146.71M	-136.82M
Adj. Free Cash Flow	-5.28M	-5.28M	-13.98M	-19.42M	-171.89M	-157.69M
Maintenance CapEx	n/a	n/a	n/a	n/a	n/a	-283K
Growth CapEx	-277K	-277K	-130K	-105K	-20.42M	n/a
Owner Earnings	25.69M	25.69M	13.3M	5.81M	-126.3M	-136.82M